AORT logo

AORT

Artivion, Inc.NYSEHealthcare
$34.21+0.15%ClosedMarket Cap: $1.64B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

167.70

PEG

0.97

P/B

3.55

P/S

3.63

EV/EBITDA

31.03

DCF Value

$-2.29

FCF Yield

-0.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

63.6%

Operating Margin

6.9%

Net Margin

2.2%

ROE

2.4%

ROA

1.1%

ROIC

2.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$116.0M$2.4M$0.05
FY 2025$441.3M$9.8M$0.21
Q3 2025$113.4M$6.5M$0.13
Q2 2025$113.0M$1.3M$0.03

Analyst Ratings

View All
Canaccord GenuityBuy
2026-02-13
NeedhamBuy
2026-02-02
Canaccord GenuityBuy
2025-11-07
CitizensMarket Outperform
2025-11-07
NeedhamBuy
2025-11-07

Trading Activity

Insider Trades

View All
Horton Amyofficer: VP, Chief Accounting Officer
SellWed Mar 04
Horton Amyofficer: VP, Chief Accounting Officer
SellWed Mar 04
Holloway Jean Fofficer: SVP, General Counsel
SellWed Mar 04
Holloway Jean Fofficer: SVP, General Counsel
SellWed Mar 04
Holloway Jean Fofficer: SVP, General Counsel
SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NYSE

Beta

1.62

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

Peers